Objective Stevia is a new nonnutritive sweetener representing a family of glycosides, in particular rebaudioside A. To evaluate glycemic effect of rebaudioside A, Erythritol(Sweete GI-0) as a sweetener in peoples with glucose intolerance. Methods This trial evaluated the glycemic effects of 2 weeks of consumption of 16 mg rebaudioside A , 986 mg erythritol (n = 25) as a sweetener in peoples with prediabets and type 2 diabetes mellitus. Those patients was performed 75 g OGTT before and after had Sweetr GI-0. Primary outcome was the change from baseline to end of treatment in fructosamine level. Secondary end points were change from baseline to end of treatment in fasting plasma glucose level and 75 g OGTT. Results Change in fructosamine level from baseline to end periods for Sweete GI-0 did not differ significantly (244.0 ± 19.6 vs. 241.7 ± 23.4, P = 0.3657). Changes from baseline to end study for Sweete GI-0 in fasting plasma glucose (102.6 ± 10.7 mg/dL vs. 101.3 ± 9.2 mg/dL), 75g OGTT (154.9 ± 54.3 mg/dL vs. 141.9 ± 42.2 mg/dL), insulin (7.6 ± 4.3 IU/mL vs. 7.2 ± 5.1 IU/mL) and C-peptide (2.9 ± 1.6 ng/mL vs. 2.7 ± 1.3 ng/mL) did not differ significantly (P > 0.05 for all). Assessments of change in blood pressure, body weight, and fasting total cholesterol showed no differences by treatment. Sweete GI-0 was well tolerated and records of adverse events did not differ during study periods. Conclusion We suggest that consumption of sweetener, Sweete GI-0 dose not alter glucose homeostasis in peoples with glucose intolerance.